Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician associates, pharmacists, social workers, and other health care professionals who treat patients with breast cancer.

Learning Objectives

The goal of the program is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

Summarize the current recommendations for oncology care, key updates in the NCCN Guidelines^®, and clinical research updates from the 2025 SABCS and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer.
Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.
Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with cancer and the delivery of oncology care.

Additional information

Supporters:

This activity is supported by educational grants from:

AstraZeneca
Lilly
Menarini-Stemline
Novartis
Puma Biotechnology

This activity is supported through independent educational grants from:

Daiichi Sankyo
Merck & Co., Inc., Rahway, NJ, USA.

Supported by a grant from Pfizer Inc.

Course summary

Course opens:

03/15/2026

Course expires:

03/14/2027

Cost:

$50.00

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Bethany M. Anderson, MD
Ann Marie Flores, PhD, MA, PT
Tuya Pal, MD
Laura H. Rosenberger, MD, MS
Wafa Samara, PharmD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Meghan R. Flanagan, MD, MPH
Intuitive Surgical, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Perimeter Medical Imaging AI: Grant/Research Support

Lisa E. Flaum, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Biotheranostics: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

Frederick M. Howard, MD
Leica Biosystems: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Irene Kang, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
BioNTech: Consulting Fee
Caris Life Sciences: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc. Consulting Fee
Menarini Stemline: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee

Melissa M. McShane, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee

Melinda L. Telli, MD
Arvinas: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BioNTech: Grant/Research Support; Scientific Advisor
Blueprint Medicines: Scientific Advisor
Celcuity: Consulting Fee
Foresight Diagnostics: Scientific Advisor
G1 Therapeutics: Consulting Fee
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Lilly: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Natera: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
OncoSec Medical: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Summit Therapeutics: Scientific Advisor

Kay T. Yeung, MD, PhD
Alterome Therapeutics: Grant/Research Support
Arvinas: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BioFluidica: Grant/Research Support
BriaCell Therapeutics: Grant/Research Support
Dantari, Inc.: Grant/Research Support
Endeavor BioMedicines: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Greenwich Therapeutics: Grant/Research Support
Iambic Therapeutics: Grant/Research Support
Immunomedics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
MOMA Therapeutics: Grant/Research Support
OBI Pharma: Grant/Research Support
OnKure Therapeutics: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Poseidon Therapeutics: Grant/Research Support
Pyxis Oncology: Grant/Research Support
Regeneron Pharmactcls: Grant/Research Support
Regor Therapeutics: Grant/Research Support
Relay Therapeutics: Grant/Research Support
SeaGen: Grant/Research Support
Stemline Therapeutics: Grant/Research Support
Zymeworks: Grant/Research Support

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This program has been approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, ABS, and ABMS MOC points for physicians and will award contact hours for nurses, pharmacists, physician associates and other health care professionals.

Complete accreditation information is provided before each individual educational activity.

Status

Price

Title

Locked

$50.00Included

Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium